191 related articles for article (PubMed ID: 12036410)
1. Ras/Raf signalling and emerging pharmacotherapeutic targets.
Kolch W
Expert Opin Pharmacother; 2002 Jun; 3(6):709-18. PubMed ID: 12036410
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.
Romerio F; Riva A; Zella D
Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503
[TBL] [Abstract][Full Text] [Related]
3. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
Collisson EA; De A; Suzuki H; Gambhir SS; Kolodney MS
Cancer Res; 2003 Sep; 63(18):5669-73. PubMed ID: 14522881
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells.
Anders M; Christian C; McMahon M; McCormick F; Korn WM
Cancer Res; 2003 May; 63(9):2088-95. PubMed ID: 12727824
[TBL] [Abstract][Full Text] [Related]
5. cAMP inhibits the proliferation of retinal pigmented epithelial cells through the inhibition of ERK1/2 in a PKA-independent manner.
Hecquet C; Lefevre G; Valtink M; Engelmann K; Mascarelli F
Oncogene; 2002 Sep; 21(39):6101-12. PubMed ID: 12203122
[TBL] [Abstract][Full Text] [Related]
6. Leukotriene D(4) activates MAPK through a Ras-independent but PKCepsilon-dependent pathway in intestinal epithelial cells.
Paruchuri S; Hallberg B; Juhas M; Larsson C; Sjölander A
J Cell Sci; 2002 May; 115(Pt 9):1883-93. PubMed ID: 11956320
[TBL] [Abstract][Full Text] [Related]
7. P2Y(2) receptor-mediated proliferation of C(6) glioma cells via activation of Ras/Raf/MEK/MAPK pathway.
Tu MT; Luo SF; Wang CC; Chien CS; Chiu CT; Lin CC; Yang CM
Br J Pharmacol; 2000 Apr; 129(7):1481-9. PubMed ID: 10742305
[TBL] [Abstract][Full Text] [Related]
8. The Ras-Raf-MEK-ERK pathway in the treatment of cancer.
Hilger RA; Scheulen ME; Strumberg D
Onkologie; 2002 Dec; 25(6):511-8. PubMed ID: 12566895
[TBL] [Abstract][Full Text] [Related]
9. The kinase domain of MEKK1 induces apoptosis by dysregulation of MAP kinase pathways.
Boldt S; Weidle UH; Kolch W
Exp Cell Res; 2003 Feb; 283(1):80-90. PubMed ID: 12565821
[TBL] [Abstract][Full Text] [Related]
10. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration.
Rajalingam K; Wunder C; Brinkmann V; Churin Y; Hekman M; Sievers C; Rapp UR; Rudel T
Nat Cell Biol; 2005 Aug; 7(8):837-43. PubMed ID: 16041367
[TBL] [Abstract][Full Text] [Related]
11. Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway.
Woods D; Cherwinski H; Venetsanakos E; Bhat A; Gysin S; Humbert M; Bray PF; Saylor VL; McMahon M
Mol Cell Biol; 2001 May; 21(9):3192-205. PubMed ID: 11287623
[TBL] [Abstract][Full Text] [Related]
12. Development of anticancer drugs targeting the MAP kinase pathway.
Sebolt-Leopold JS
Oncogene; 2000 Dec; 19(56):6594-9. PubMed ID: 11426644
[TBL] [Abstract][Full Text] [Related]
13. Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells.
Lefevre G; Calipel A; Mouriaux F; Hecquet C; Malecaze F; Mascarelli F
Oncogene; 2003 Dec; 22(55):8813-22. PubMed ID: 14654778
[TBL] [Abstract][Full Text] [Related]
14. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade.
Kim PN; Jonasch E; Mosterman BC; Mier JW; Janssen RA
Cell Growth Differ; 2001 Nov; 12(11):543-50. PubMed ID: 11714635
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention.
Herrera R; Sebolt-Leopold JS
Trends Mol Med; 2002; 8(4 Suppl):S27-31. PubMed ID: 11927284
[TBL] [Abstract][Full Text] [Related]
16. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
[TBL] [Abstract][Full Text] [Related]
17. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
18. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.
Chang F; Steelman LS; Lee JT; Shelton JG; Navolanic PM; Blalock WL; Franklin RA; McCubrey JA
Leukemia; 2003 Jul; 17(7):1263-93. PubMed ID: 12835716
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel Raf kinase inhibitor.
Lyons JF; Wilhelm S; Hibner B; Bollag G
Endocr Relat Cancer; 2001 Sep; 8(3):219-25. PubMed ID: 11566613
[TBL] [Abstract][Full Text] [Related]
20. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt.
Rommel C; Clarke BA; Zimmermann S; Nuñez L; Rossman R; Reid K; Moelling K; Yancopoulos GD; Glass DJ
Science; 1999 Nov; 286(5445):1738-41. PubMed ID: 10576741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
